secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2022-11-30T23:59:59+00:00
Accession:  0001640334-22-002533
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria Bioscience: DehydraTECH-CBD shows better seizure control at lower doses vs. Epidiolex in animal study
--------------------------------------------------------------------------------

- Pilot study: at 50 mg/kg, only DehydraTECH-CBD showed seizure reduction; at 75 mg/kg, full elimination in 66.6% of animals vs. 50% for Epidiolex.
- Time to peak efficacy: at 30 min, 50% of DehydraTECH-CBD animals had partial/full seizure elimination vs. 0% for Epidiolex; at 60 min, 87.5% vs. 62.5%.
- ED50 study (dose for 50% seizure inhibition) is underway; results will be reported separately.
- Study EPIL-A21-1 uses MES model in rats; fully funded by Lexaria and performed by a US independent lab.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033422002533/0001640334-22-002533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033422002533/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-22-002533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer